Explaining end-users' intentions to use innovative medical and food biotechnology products

Files

Access status: Embargo until 2050-01-01 , 997_ftp.pdf (166.21 KB)

Publication date

2014-01-01

Authors

Mulder, Bob C.
Poortvliet, P. Marijn
Lugtig, PeterORCID 0000-0001-8106-2147ISNI 0000000389317698
de Bruin, Marijn

Editors

Advisors

Supervisors

Document Type

Article

License

Abstract

Low public acceptance hinders the successful introduction of biotechnological innovations, such as genetically modified foods or vaccinations against infectious diseases. Earlier studies indicated that a lack of knowledge is not a key barrier to acceptance. This was confirmed in the current study, which examined an integrated theoretical model tested among 579 participants from the Dutch public. The results suggest that communication strategies should instead target attitudes, social norms, and risk perceptions, and appeal to people's tendency (or lack thereof) to be innovative.

Keywords

Applied Microbiology and Biotechnology, Molecular Medicine, SDG 3 - Good Health and Well-being

Citation

Mulder, B C, Poortvliet, P M, Lugtig, P & de Bruin, M 2014, 'Explaining end-users' intentions to use innovative medical and food biotechnology products', Biotechnology Journal, vol. 9, no. 8, pp. 997-999. https://doi.org/10.1002/biot.201400224